Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7571242 | 1.00 | ALDH1A1 (0.32) | ALDH1A1POLBCA1CA2 | |
| SCHEMBL4162965 | 1.00 | ALDH1A1 (0.32) | ALDH1A1POLBCA1CA2 | |
| SCHEMBL7090122 | 0.86 | — | — | |
| SCHEMBL9786210 | 0.85 | ALDH1A1 (0.32) | ALDH1A1POLBCA1CA2 | |
| SCHEMBL9625028 | 0.83 | ALDH1A1 (0.37) | ALDH1A1POLBCA1CA2 | |
| SCHEMBL2002567 | 0.79 | HCRTR2 (0.32) | ALDH1A1POLB | |
| SCHEMBL12568779 | 0.79 | HCRTR2 (0.32) | ALDH1A1POLB | |
| SCHEMBL14330425 | 0.77 | YWHAZ (0.36) | CA1CA2 | |
| SCHEMBL14330424 | 0.75 | YWHAZ (0.35) | CA1CA2 | |
| SCHEMBL16135488 | 0.74 | MAPK1 (0.39) | ALDH1A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541020-B2 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | CORIXA CORPORATION (US) | 2009-06-02 | — | — | US | disclosed |
| US-7063967-B2 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | CORIXA CORPORATION (US) | 2006-06-20 | — | — | US | disclosed |
| EP-0983286-B1 | AMINOALKYL GLUCOSAMINE PHOSPHATE COMPOUNDS AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS | CORIXA CORP (US) | 2004-07-28 | — | — | EP | disclosed |
| EP-1105401-B1 | PHOSPHOGLYCOLIPID AND METHODS FOR ITS USE | CORIXA CORP (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20030199460-A1 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | CORIXA CORPORATION (US) | 2003-10-23 | — | — | US | disclosed |
| US-20030092643-A1 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | CORIXA CORPORATION | 2003-05-15 | — | — | US | disclosed |
| EP-1230250-A2 | AMINOALKYL GLUCOSAMINIDE PHOSPHATE COMPOUNDS AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS | CORIXA CORPORATION (US) | 2002-08-14 | — | — | EP | disclosed |
| US-6355257-B1 | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors | CORIXA CORPORATION | 2002-03-12 | — | — | US | disclosed |
| US-20020013291-A1 | Phosphoglycolipid and methods for its use | CORIXA CORPORATION | 2002-01-31 | — | — | US | disclosed |
| US-6303347-B1 | VACCINES | CORIXA CORPORATION | 2001-10-16 | — | — | US | disclosed |
| EP-1105401-A1 | PHOSPHOGLYCOLIPID AND METHODS FOR ITS USE | CORIXA CORPORATION (US) | 2001-06-13 | — | — | EP | disclosed |
| WO-2001034617-A2 | AMINOALKYL GLUCOSAMINIDE PHOSPHATE COMPOUNDS AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS | CORIXA CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
| US-6113918-A | IMMUNOLOGY | RIBI IMMUNOCHEM RESEARCH, INC. (US) | 2000-09-05 | — | — | US | disclosed |
| EP-0983286-A1 | AMINOALKYL GLUCOSAMINE PHOSPHATE COMPOUNDS AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS | CORIXA CORPORATION (US) | 2000-03-08 | — | — | EP | disclosed |
| WO-2000011010-A1 | PHOSPHOGLYCOLIPID AND METHODS FOR ITS USE | CORIXA CORPORATION (US) | 2000-03-02 | — | — | WO | disclosed |
| US-6013640-A | ANTIISCHEMIC AGENTS | RIBI IMMUNOCHEM RESEARCH, INC. (US) | 2000-01-11 | — | — | US | disclosed |
| WO-1998050399-A1 | AMINOALKYL GLUCOSAMINE PHOSPHATE COMPOUNDS AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS | CORIXA CORPORATION (US) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199460-A1 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | DNPEP, CD68, MGAT3 | ALDH1A1 3027/4885POLB 2834/4885CA1 2470/4885 |
| US-20030092643-A1 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | DNPEP, CD68, MGAT3 | ALDH1A1 3027/4885POLB 2834/4885CA1 2470/4885 |
| US-20020013291-A1 | Phosphoglycolipid and methods for its use | PYGL, GPI, PNLIP | ALDH1A1 2330/4885POLB 3152/4885CA1 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.